Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Alnylam Pharmaceuticals has received an average recommendation of "Moderate Buy" from twenty-nine analysts, with a 1-year price target averaging $448.04.
• Insider selling has occurred recently, with executives Kevin Joseph Fitzgerald and Tolga Tanguler each selling shares, decreasing their ownership by 8.82% and 4.87% respectively.
• The company reported $773.69 million in revenue for the last quarter, which is a 17.3% increase from the same period last year, while also surpassing EPS expectations with a profit of $0.32.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty-nine analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-four have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $448.0404.

ALNY has been the subject of several recent analyst reports. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a report on Friday, August 1st. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a "buy" rating in a report on Monday. UBS Group raised their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday, August 1st. Chardan Capital raised their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Barclays raised their price target on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president owned 25,231 shares of the company's stock, valued at $11,405,673.55. This trade represents a 8.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Tolga Tanguler sold 1,405 shares of the firm's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $635,130.25. Following the sale, the executive vice president directly owned 27,438 shares of the company's stock, valued at $12,403,347.90. This represents a 4.87% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $27,000. Bessemer Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $30,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $37,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $42,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Down 1.0%

NASDAQ ALNY opened at $452.00 on Tuesday. The company has a market cap of $59.25 billion, a PE ratio of -183.00 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $484.21. The stock has a 50 day moving average of $444.12 and a 200-day moving average of $341.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.